Tandem Diabetes Care Inc (NASDAQ:TNDM) Stock Position Raised by Dupont Capital Management Corp

Dupont Capital Management Corp raised its position in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) by 3.7% in the third quarter, Holdings Channel reports. The firm owned 17,535 shares of the medical device company’s stock after buying an additional 626 shares during the period. Dupont Capital Management Corp’s holdings in Tandem Diabetes Care were worth $1,034,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in shares of Tandem Diabetes Care by 53.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after purchasing an additional 160 shares in the last quarter. TRUE Private Wealth Advisors purchased a new stake in shares of Tandem Diabetes Care during the 2nd quarter worth about $33,000. First Quadrant L P CA bought a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $34,000. James Investment Research Inc. raised its stake in shares of Tandem Diabetes Care by 15.9% in the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 180 shares in the last quarter. Finally, Stephens Inc. AR bought a new position in shares of Tandem Diabetes Care in the 2nd quarter valued at approximately $113,000. 79.90% of the stock is owned by institutional investors.

TNDM opened at $62.35 on Friday. The company has a quick ratio of 2.21, a current ratio of 2.53 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $3.70 billion, a P/E ratio of -24.45 and a beta of 0.19. Tandem Diabetes Care Inc has a 12-month low of $26.40 and a 12-month high of $74.81. The stock’s 50 day moving average price is $60.58 and its two-hundred day moving average price is $63.72.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.20. The business had revenue of $93.26 million during the quarter, compared to the consensus estimate of $69.95 million. Tandem Diabetes Care had a negative return on equity of 19.31% and a negative net margin of 19.55%. Tandem Diabetes Care’s revenue was up 173.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.33) EPS. As a group, analysts anticipate that Tandem Diabetes Care Inc will post -0.46 earnings per share for the current year.

A number of brokerages recently weighed in on TNDM. UBS Group raised Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Friday, October 4th. BidaskClub downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Friday. ValuEngine raised Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research note on Friday. Oppenheimer raised their price objective on Tandem Diabetes Care from $80.00 to $84.00 in a research note on Friday, August 2nd. Finally, Guggenheim began coverage on Tandem Diabetes Care in a research note on Thursday, October 17th. They issued a “buy” rating and a $76.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $75.31.

In related news, EVP David B. Berger sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $72.00, for a total transaction of $144,000.00. Following the completion of the transaction, the executive vice president now owns 5,311 shares in the company, valued at approximately $382,392. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Howard E. Greene, Jr. sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $61.50, for a total value of $615,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 455,221 shares of company stock valued at $31,849,205 in the last 90 days. 6.90% of the stock is owned by corporate insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Trade Deficit

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.